CTRI/2012/05/002632已完成未知
An open label, balanced, randomized, two treatment, two-period, two-sequence, crossover, multicentricexperimental bioequivalence study comparing Quetiapine film coated tablets 300 mg (Manufactured by HeteroLabs Limited, India) to the reference listed drug Seroquel® film coated tablets 300mg (Manufactured by AstraZeneca USA) under fasting conditions after multiple dose administration at steady state in adultschizophrenic patients stabilized on Quetiapine 600 mg per day.
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1. Patient has a documented clinical diagnosis of schizophrenia (DSM IV-TR) and on a stable dose of Quetiapine 600 mg per day for at least 10 days prior to screening.
- •2. Having a Body Mass Index (BMI) between 18 and 30 (both inclusive), calculated as weight in kg / height in m2.
- •3. The investigator must ensure that the respective hepatic, renal, haematopoietic, cardiac and respiratory functions are appropriate to include the patient in the study.
- •4. Able to comply with study procedures in the opinion of the investigator.
- •5. Sexually active women, unless surgically sterile (at least 6 months prior to Study drug administration) or postmenopausal for at least 12 consecutive months, must use an effective method of avoiding pregnancy (including oral, transdermal, or implanted contraceptives [any hormonal method in conjunction with a secondary method], intrauterine device, female condom with spermicide, diaphragm with spermicide, absolute sexual abstinence, use of condom with spermicide by sexual partner or sterile [at least 6 months prior to Study drug administration] sexual partner) for at least 4 weeks prior to study drug administration, during study and up to 30 days after the last dose of study drug. Cessation of birth control after this point should be discussed with a responsible physician.
- •6. In case of Male patients: Either partner or patient must use an effective method of avoiding pregnancy for at least 4 weeks prior to study drug administration, during study and up to 30 days after the last dose of study drug. Cessation of birth control after this point should be discussed with a responsible physician.
排除标准
- •1. Known hypersensitivity or idiosyncratic reaction to Quetiapine and its excipients.
- •2. Current or relevant history of serious, severe or unstable psychiatric illness except schizophrenia.
- •3. Presence of Postural Hypotension (Defined as systolic blood pressure decrease of at least 20 mmHg or a diastolic blood pressure decrease of at least 10 mmHg within three minutes of standing up).
- •4. History of syncope or orthostatic hypotension.
- •5. A recent history of alcoholism (less than 2 years) or daily consumption of moderate (180 mL/day) alcohol use, or consumption of alcohol or alcoholic products within 48 hour prior to receiving study medication or inability to abstain from alcohol during the study.
- •6. Smokers who has inability to abstain from smoking during the study.
- •7. Known case of HIV infection.
- •8. Any condition/ Abnormal baseline findings that in the investigatorâ??s judgement might increase the risk to the patient or decrease the chance of obtaining satisfactory data needed to obtain the objective of the study.
- •9. Hospitalisation for an exacerbation of schizophrenia within two months prior to screening and during the screening period.
- •10. Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others.
- •11. History of agranulocytosis.
- •12. Pregnant or lactating females.
研究者
相似试验
已完成
2 期
An open label, balanced, randomized, two treatment, two period, two sequence, cross over, comparative bioavailability study of a single dose of commercially available 6 gm Curcumin hard gelatin capsules (each capsule contains 500 mg of Curcumin 95%) and 6 gm Curcumin soft gelatin capsules (each capsule contains 750 mg of Curcumin 95%) of Amsar Private Limited, in healthy human adult male subjects under fed condition.CTRI/2009/091/000327Amsar Private limited30
已完成
不适用
A Bioequivalence study to compare the Bioequivalence of two formulation of quetiapine in schizophrenic patients.CTRI/2010/091/000181Dr Reddys Laboratories Ltd India54
招募中
不适用
Bioequivalencestudy of Lomustine 40mg capsulesCTRI/2022/11/047029Carnegie Pharmaceuticals
招募中
不适用
Bioequivalence study ofCapecitabine tablets 500 mgCTRI/2018/05/014342Mega Pharma SA
已完成
不适用
A study to evaluate the bioequivalence of Quetiapine with Seroquel in adult schizophrenic patients.CTRI/2010/091/000001Intas Pharmaceuticals Ltd48